Valuation: Aquestive Therapeutics, Inc.

Market Cap 462M 406M 377M 346M 650M 44.46B 660M 4.48B 1.75B 21.86B 1.73B 1.7B 75.58B P/E 2026 *
-9.09x
P/E 2027 * -9.48x
Enterprise Value 377M 331M 308M 282M 531M 36.28B 539M 3.65B 1.43B 17.84B 1.41B 1.38B 61.67B EV / Sales 2026 *
7.46x
EV / Sales 2027 * 6.42x
Free-Float
96.94%
Yield 2026 *
-
Yield 2027 * -
1 day-2.39%
1 week-10.68%
Current month-11.54%
1 month-17.58%
3 months-9.80%
6 months+13.58%
Current year-43.03%
1 week 3.64
Extreme 3.64
4.18
1 month 3.64
Extreme 3.64
4.38
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
16/7/26 Sell

Chief Executive Officer

-20,369 0.0162%
23/6/26 Fiscal year

Director

75,000 0.0598%
15/6/26 Sell

Chief Executive Officer

-25,000 0.0199%
Change 5-day change 1-year change 3-year change Capi.($)
-2.39%-10.68%-11.33%+130.00% 462M
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
+1.60%+6.25%+37.00%+30.00% 347B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
Average +0.20%+0.13%+22.45%+60.13% 364.4B
Weighted average by Cap. +0.76%+1.95%+35.99%+78.15%

Financials

2026 *2027 *
Net sales 50.51M 44.36M 41.26M 37.86M 71.14M 4.86B 72.23M 490M 191M 2.39B 190M 186M 8.27B 71.92M 63.16M 58.74M 53.9M 101M 6.93B 103M 698M 273M 3.4B 270M 264M 11.77B
Net income -50.65M -44.48M -41.37M -37.96M -71.33M -4.88B -72.43M -491M -192M -2.4B -190M -186M -8.29B -47.99M -42.15M -39.2M -35.97M -67.59M -4.62B -68.63M -466M -182M -2.27B -180M -176M -7.86B
Net Debt -85M -74.66M -69.43M -63.71M -120M -8.19B -122M -824M -322M -4.02B -319M -312M -13.91B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
24/07/26 USD 3.680 -2.39% 2,881,478
23/07/26 USD 3.770 -4.31% 2,015,861
22/07/26 USD 3.940 -2.48% 1,707,558
21/07/26 USD 4.040 +2.41% 1,797,137
20/07/26 USD 3.945 -4.25% 1,434,370
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.680USD
Average target price
8.889USD
Spread / Average Target
+141.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock